



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

November 22, 2023

Timothy E. Sullivan  
Chief Financial Officer and Treasurer  
Apellis Pharmaceuticals, Inc.  
100 Fifth Avenue  
Waltham, MA 02451

**Re: Apellis Pharmaceuticals, Inc.**  
**Form 10-K for the Fiscal Year Ended December 31, 2022**  
**Filed February 21, 2023**  
**Form 10-Q for the period ended September 30, 2023**  
**Filed November 1, 2023**  
**File No. 001-38276**

Dear Timothy E. Sullivan:

We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences